Cardiac complications during DLBCL treatment using R-CHOP Case report
Article Sidebar
Main Article Content
Abstract
Diffuse large B‐cell lymphoma (DLBCL) is the most frequent of non-Hodgkin’s lymphomas in the world. Immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R‐CHOP) is the first-line treatment in this disease. Rituximab is a chimeric murine-human monoclonal anti-CD20 antibody, which binds specifically with CD20 receptor located on majority of mature B-cell lymphocytes. We are presenting the case of sudden cardiac arrest with ventricular fibrillation after intravenous injection of rituximab in a patient with DLBCL type NGC.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Ziepert M, Hasenclever D, Kuhnt E et al. Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20 B-Cell Lymphoma in the Rituximab Era. J Clin Oncol 2010; 28: 14.
3. Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010; 9: 116.
4. Martelli M, Ferreri AJM, Agostinelli C et al. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013; 87: 146-171.
5. Seruga B, Sterling L, Wang L, Tannock IF. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 2011; 29: 174-185.
6. Foran JM, Rohatiner AZS, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317-324.
7. Poterucha JT, Westberg M, Nerheim P, Lovell JP. Rituximab-Induced Polymorphic Ventricular Tachycardia. Tex Heart Inst J 2010; 37(2): 218-220.
8. Lee L, Kukreti V. Rituximab-Induced Coronary Vasospasm. Case Rep Hematol 2012. Article ID 984986. https://doi.org/10.1155/2012/984986.
9. Ke C, Khosla A, Davis MK et al. A Case of Coronary Vasospasm after Repeat Rituximab Infusion. Case Rep Cardiol 2015. Article ID 523149. https://doi.org/10.1155/2015/523149.
10. Naqvi SY, Hanley A, Crowley J. Ventricular fibrillation due to coronary vasospasm. BMJ Case Rep 2014. https://doi.org/10.1136/bcr-2013-203253.
11. Arenja N, Zimmerli L, Urbaniak P, Vogel R. Acute anterior myocardial infarction after rituximab. Dtsch Med Wochenschr 2016; 141: 500-503. https://doi.org/10.1055/s-0041-106055.
12. Bambury R, Gallagher F, Dodd JD, Fennelly D. Primary cardiac lymphoma: diagnostic tools and treatment challenges. Ir J Med Sci 2011; 180: 271-273. https://doi.org/10.1007/s11845-009-0446-x.
13. Ng KH, Dearden C, Gruber P. Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears? BMJ Case Rep 2015. https://doi.org/10.1136/bcr2014-208203.
14. Arai Y, Tadokoro J, Mitani K. Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma. Am J Hematol 2005; 78: 316-319. https://doi.org/10.1002/ajh.20303.
15. Janas E, Priest R, Malhotra R. Functional role of lipid rafts in CD20 activity? Biochem Soc Symp 2005; 72: 165-175.
16. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8: 140-174.